Psoriatic Arthritis News

Patients with nail psoriasis alongside psoriatic arthritis demonstrate worse disease activity, quality of life and work productivity than those without nail involvement, according to data published in The Journal of Rheumatology.

Biosimilar use among Medicare fee-for-service beneficiaries seems to depend most on practice setting and hospital ownership status, with few patient or physician characteristics linked to usage, according to data in JAMA Network Open.

While novel drugs are changing the game in psoriatic arthritis, early diagnosis and interdisciplinary management remain keys to successful outcomes, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Secukinumab is effective in psoriatic arthritis at 6 and 12 months, with significantly better remission, low disease activity, retention and response rates in patients naïve to disease-modifying antirheumatic drugs, according to data.

A greater percentage of patients with psoriatic arthritis achieve remission with biologic therapy than those with rheumatoid arthritis, at both 1- and 12-year follow-up, according to data published in Arthritis Research & Therapy.

Depression rates were lower in patients treated with apremilast monotherapy for psoriasis or psoriatic arthritis and higher in those treated with biologics, corticosteroids and non-apremilast combinations, according to a presentation.

The European Commission has extended approval for AbbVie’s upadacitinib 15 mg to treat adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis, according to a company press release.

The National Psoriasis Foundation’s COVID-19 task force has updated its guidelines for managing psoriatic disease during the pandemic.

There is no increased risk for solid cancer, or eight common cancer types, among patients with psoriatic arthritis who receive TNF inhibitors, according to data published in Rheumatology.

Patients being treated with tumor necrosis factor inhibitors or methotrexate who acquired COVID-19 did not experience elevated hospitalization or mortality rates, according to a study.